F S&P 500
5,118.00 +35.75 (+0.70%) F Dow Jones
38,319.00 +31.00 (+0.08%) F Nasdaq
17,736.00 +168.50 (+0.96%) E-mini Russell 2000 Index Futur
1,991.60 -1.60 (-0.08%) Petróleo
84.37 +0.80 (+0.96%) Oro
2,355.30 +12.80 (+0.55%)
Galecto, Inc. (GLTO)
Fuera de horario:
Galecto, Inc.
Ole Maaloes Vej 3
Copenhagen N
Copenhagen 2200
Denmark
45 70 70 52 10
https://galecto.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 13
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Hans T. Schambye M.D., Ph.D. | Co-Founder, President, CEO & Director | 700.13k | N/D | 1966 |
| Mr. Jonathan P. Freve CPA, CPA | Chief Financial Officer | 604.93k | N/D | 1978 |
| Mr. Ulf J. Nilsson | Co-Founder | N/D | N/D | N/D |
| Dr. Hakon Leffler | Co-Founder | N/D | N/D | N/D |
| Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. | Co-Founder | N/D | N/D | N/D |
| Mr. Garrett Winslow Esq. | Senior VP, General Counsel & Corporate Secretary | N/D | N/D | 1979 |
Descripción
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Gestión corporativa
La calificación ISS Governance QuickScore de Galecto, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
